Weight change, glycemic control, and sulfonylurea use are determinants of either preservation or decline in microvascular function in patients with type 2 diabetes.
Inclusion of silent myocardial infarction in diabetes risk stratification improves risk discrimination over and beyond traditional factors.
Abnormally rapid corneal nerve fiber loss may indicate increased risk for the development and progression of diabetic distal symmetric polyneuropathy.
Insulin and other biologic drugs, have now transitioned to being regulated as biological products, providing a new pathway for approval of biosimilars and interchangeable versions of these products and introducing competition into the market.
For men, early age at puberty is associated with an increased risk for type 2 diabetes.
Among other strategies, clinicians can suggest changes to lifestyle habits, encourage sleep hygiene, and prescribe pharmacologic interventions to combat risk for metabolic syndrome in shift workers.
Increased blood glucose levels, even within the nondiabetic range, are associated with increased risk for nonalcoholic fatty liver disease.
Nonalbuminuric diabetic kidney disease is not associated with a worse prognosis than other diabetic kidney disease phenotypes.
The FDA has granted Fast Track designation for empagliflozin (Jardiance; Boehringer Ingelheim and Lilly) to reduce the risk of kidney disease progression and cardiovascular (CV) death in adults with chronic kidney disease.
The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.